慢性非卧床腹膜透析患者单剂量静脉注射、口服及腹腔注射培氟沙星的药代动力学
Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis.
作者信息
Schmit J L, Hary L, Bou P, Renaud H, Westeel P F, Andrejak M, Fournier A
机构信息
Department of Nephrology, University Hospital, Amiens, France.
出版信息
Antimicrob Agents Chemother. 1991 Jul;35(7):1492-4. doi: 10.1128/AAC.35.7.1492.
Abstract
Comparison of plasma and dialysate concentrations of pefloxacin after intravenous, oral, or intraperitoneal administration shows excellent bidirectional diffusion of the quinolone through the peritoneal membrane, demonstrating that therapeutical concentrations can be achieved in the dialysate after intravenous or oral administration. In this study, the half-life of the drug was 18.8 +/- 1.4 h, i.e., apparently longer than that reported for normal controls or uremic patients on hemodialysis.
摘要
静脉注射、口服或腹腔注射培氟沙星后，血浆和透析液浓度的比较显示，喹诺酮类药物可通过腹膜实现良好的双向扩散，这表明静脉注射或口服给药后，透析液中可达到治疗浓度。在本研究中，该药物的半衰期为18.8±1.4小时，即明显长于正常对照或接受血液透析的尿毒症患者所报告的半衰期。
相似文献
1
Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis.慢性非卧床腹膜透析患者单剂量静脉注射、口服及腹腔注射培氟沙星的药代动力学
Antimicrob Agents Chemother. 1991 Jul;35(7):1492-4. doi: 10.1128/AAC.35.7.1492.
2
Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Perit Dial Int. 1991;11(1):59-63.
3
Pharmacokinetics of pefloxacin in goats after intravenous or oral administration.
Vet Res Commun. 2002 Feb;26(2):141-9. doi: 10.1023/a:1014047702196.
4
Pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis.
J Clin Pharmacol. 1993 May;33(5):475-9. doi: 10.1002/j.1552-4604.1993.tb04691.x.
5
Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.慢性非卧床腹膜透析患者静脉及腹腔注射莫拉司亭的药代动力学
Eur J Clin Pharmacol. 1986;30(3):299-302. doi: 10.1007/BF00541532.
6
7
Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
Eur J Clin Pharmacol. 1986;31(4):479-83. doi: 10.1007/BF00613528.
8
Plasma and dialysate levels of pefloxacin and its metabolites in CAPD patients with peritonitis.伴有腹膜炎的持续性非卧床腹膜透析（CAPD）患者中培氟沙星及其代谢物的血浆和透析液水平。
J Antimicrob Chemother. 1990 Apr;25(4):657-64. doi: 10.1093/jac/25.4.657.
9
Management of peritonitis related to chronic ambulatory peritoneal dialysis (CAPD) using two daily intraperitoneal injections of 400 mg pefloxacin.
Chemioterapia. 1987 Jun;6(2 Suppl):481-3.
10
Pharmacokinetics of cefodizime during continuous ambulatory peritoneal dialysis.
J Antimicrob Chemother. 1990 Nov;26 Suppl C:89-93. doi: 10.1093/jac/26.suppl_c.89.
引用本文的文献
1
Clinical pharmacokinetics during continuous ambulatory peritoneal dialysis.持续性非卧床腹膜透析期间的临床药代动力学
Clin Pharmacokinet. 1996 Oct;31(4):293-308. doi: 10.2165/00003088-199631040-00005.
2
Pefloxacin clinical pharmacokinetics.培氟沙星的临床药代动力学。
Clin Pharmacokinet. 1994 Dec;27(6):418-46. doi: 10.2165/00003088-199427060-00003.
本文引用的文献
1
Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.甲磺酸培氟沙星在小鼠、大鼠、犬、猴及人体内的吸收、分布、代谢转归及消除
Antimicrob Agents Chemother. 1984 Apr;25(4):463-72. doi: 10.1128/AAC.25.4.463.
2
Microbiologic aspects of chronic ambulatory peritoneal dialysis.慢性非卧床腹膜透析的微生物学方面
Kidney Int. 1983 Jan;23(1):83-92. doi: 10.1038/ki.1983.15.
3
Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies.持续性非卧床腹膜透析中的腹膜炎。实验室及临床研究。
Lancet. 1982 Dec 18;2(8312):1388-91. doi: 10.1016/s0140-6736(82)91282-x.
4
Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
Clin Pharmacol Ther. 1985 Jul;38(1):31-6. doi: 10.1038/clpt.1985.130.
5
Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.接受腹膜透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1985 Sep-Oct;10(5):404-25. doi: 10.2165/00003088-198510050-00003.
6
Pharmacokinetics of pefloxacin in renal insufficiency.
Eur J Clin Pharmacol. 1985;29(3):345-9. doi: 10.1007/BF00544092.
7
Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience.
Nephron. 1986;43(2):105-9. doi: 10.1159/000183807.
8
Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment.
Eur J Clin Pharmacol. 1987;33(5):463-7. doi: 10.1007/BF00544236.
9
Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.培氟沙星在年轻健康志愿者中多次静脉注射和口服给药（400毫克，每日两次）后的药代动力学。
J Antimicrob Chemother. 1986 Apr;17 Suppl B:65-79. doi: 10.1093/jac/17.suppl_b.65.
10
[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics].
Pathol Biol (Paris). 1987 May;35(5):652-5.
Zotero 插件